GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » 3-Year Revenue Growth Rate

Alkermes (Alkermes) 3-Year Revenue Growth Rate : 14.40% (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Alkermes 3-Year Revenue Growth Rate?

Alkermes's Revenue per Share for the three months ended in Dec. 2023 was $2.26.

During the past 12 months, Alkermes's average Revenue per Share Growth Rate was 44.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 14.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 4.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 8.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Alkermes was 69.60% per year. The lowest was -20.20% per year. And the median was 11.30% per year.


Competitive Comparison of Alkermes's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Alkermes's 3-Year Revenue Growth Rate falls into.



Alkermes 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Alkermes  (NAS:ALKS) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Alkermes 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Alkermes's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (Alkermes) Business Description

Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Executives
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols officer: SVP, Chief Commercial Officer 852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr. director ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright director C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine officer: SVP, Corp Dev., Alkermes, Inc. 88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops director, officer: Director and CEO, Alkermes plc 10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke officer: President, Alkermes plc TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson officer: EVP, Chief Operating Officer 852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md director 37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson officer: SVP, Med Dev/Med Affairs, CMO 852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown officer: VP, Finance & CAO 14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon director IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin officer: SVP, CLO, Alkermes, Inc. 852 WINTER STREET, WALTHAM MA 02451